Investigation of Circulating MicroRNA Levels in Antibody-Mediated Rejection After Kidney Transplantation

被引:1
|
作者
Nagy, Peter Ferenc [1 ]
Pocsi, Marianna [2 ]
Fejes, Zsolt [2 ]
Bidiga, Laszlo [3 ]
Szabo, Eszter [1 ]
Balogh, Orsolya [1 ]
Szollosi, Gergo Jozsef [4 ]
Nagy, Bela, Jr. [2 ]
Nemes, Balazs [1 ]
机构
[1] Univ Debrecen, Fac Med, Inst Surg, Dept Organ Transplantat, Debrecen, Hungary
[2] Univ Debrecen, Fac Med, Dept Lab Med, Debrecen, Hungary
[3] Univ Debrecen, Fac Med, Dept Pathol, Debrecen, Hungary
[4] Univ Debrecen, Fac Publ Hlth, Dept Intervent Epidemiol, Debrecen, Hungary
关键词
EXPRESSION;
D O I
10.1016/j.transproceed.2022.10.044
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. One of the most important possible complications determining long-term graft survival after kidney transplant is antibody-mediated rejection (ABMR). The criterion standard approach to recognize ABMR is currently the kidney biopsy with histopathologic analysis. However, this test has limitations because of difficulties in timing of sampling, the evaluability of histology because of the questionable representativeness of specimens, and the limited number of this intervention. Hence, new reliable, noninvasive biomarkers are required to detect the development of ABMR in time. Methods. In this study, we analyzed the clinical data of 45 kidney transplant patients (mean age of 44.51 years, 20 male and 25 female subjects). These participants were recruited into 5 subcohorts based on their clinical status, histologic findings, and level of donor-specific anti-HLA antibodies. Circulating microRNAs (miR-21, miR-181b, miR-146a, miR-223, miR-155, miR-150) in plasma samples were quantified by quantitative polymerase chain reaction and their levels were correlated with the clinical characteristics in different subgroups. Results. The relative expression of plasma miR-155 (P = .0003), miR-223 (P = .0316), and miR-21 (P = .0147) were significantly higher in patients who had subsequent histology-approved ABMR with donor-specific anti-HLA antibody positivity (n = 10) than in the "triple negative" group (n = 21), and miR-155 showed the highest sensitivity (90%) and specificity (81%) to indi-cate ABMR development based on receiver operating characteristic analysis. Conclusions. According to our preliminary data, plasma miR-155, miR-21, and miR-223 can indicate the development of ABMR after kidney transplant in correlation with classic clinical parameters. However, future studies with larger number of participants are necessary to further evaluate the diagnostic properties of blood miRNAs in prediction of this life-threatening condition.
引用
收藏
页码:2570 / 2577
页数:8
相关论文
共 50 条
  • [21] Antibody-mediated rejection after intestinal transplantation
    Dick, Andre A. S.
    Horslen, Simon
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2012, 17 (03) : 250 - 257
  • [22] Antibody-Mediated Rejection after Lung Transplantation
    Hachem, R. R.
    Ritter, J. P.
    Yusen, R. D.
    Wills, A. R.
    Iuppa, J. A.
    Byers, D.
    Mohanakurnar, T.
    Patterson, A.
    Trulock, E. P.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S36 - S37
  • [23] The role of complement in antibody-mediated rejection in kidney transplantation
    Mark D. Stegall
    Marcio F. Chedid
    Lynn D. Cornell
    Nature Reviews Nephrology, 2012, 8 : 670 - 678
  • [24] The Challenge of Acute Antibody-Mediated Rejection in Kidney Transplantation
    Chehade, Hassib
    Pascual, Manuel
    TRANSPLANTATION, 2016, 100 (02) : 264 - 265
  • [25] Belatacept for Chronic Antibody-Mediated Rejection in Kidney Transplantation
    Kumar, D.
    Gupta, G.
    Reeve, J.
    Sanghi, P.
    Bobba, S.
    Levy, M.
    Bhati, C.
    Kimball, P.
    Fattah, H.
    King, A.
    Massey, H.
    Halloran, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 310 - 310
  • [26] KIDNEY ALLOGRAFT HISTOLOGIC EVOLUTION AFTER TREATMENT OF ANTIBODY-MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION
    Joly, M.
    Olagne, J.
    Parissiadis, A.
    Vargas, G. Gautier
    Cognard, N.
    Muller, C.
    Perrin, P.
    Braun, L.
    Heibel, F.
    Essayidi, A.
    Moulin, B.
    Caillard, S.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 19 - 19
  • [27] Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation
    Abuazzam, Farah
    Dubrawka, Casey
    Abdulhadi, Tarek
    Amurao, Gwendolyn
    Alrata, Louai
    Alsabbagh, Dema Yaseen
    Alomar, Omar
    Alhamad, Tarek
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [28] Alemtuzumab Induction and Antibody-Mediated Rejection in Kidney Transplantation
    Noureldeen, T.
    Albekioni, Z.
    Machado, L.
    Muddana, N.
    Marcus, R. J.
    Hussain, S. M.
    Sureshkumar, K. K.
    TRANSPLANTATION PROCEEDINGS, 2014, 46 (10) : 3405 - 3407
  • [29] The Problem of Subclinical Antibody-mediated Rejection in Kidney Transplantation
    Filippone, Edward John
    Farber, John L.
    TRANSPLANTATION, 2021, 105 (06) : 1176 - 1187
  • [30] The role of complement in antibody-mediated rejection in kidney transplantation
    Stegall, Mark D.
    Chedid, Marcio F.
    Cornell, Lynn D.
    NATURE REVIEWS NEPHROLOGY, 2012, 8 (11) : 670 - 678